Adenoid Cystic Carcinoma; A Single Center 15 Years Experience and Literature Review
Celal Alandag1, Seher Nazli Kazaz2, Bengu Cobanoglu31Department of Medical Oncology, Sivas Numune Hospital, Sivas, Turkey, 2Department of Medical Oncology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey, 3Department of Otolaryngology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey
Objectives: Adenoid cystic carcinoma (ACC) is a rare tumor that arises from the salivary glands. Since it is rare, there are no consensus recommendations on its treatment strategy. Surgery, radiotherapy (RT), and systemic treatments are options We aimed to evaluate the treatment outcomes and prognostic factors in ACC. Methods: In this retrospective study; 17 ACC patients were included who were diagnosed with between January 2005 and April 2020 in Karadeniz Technical University Faculty of Medicine. We analyzed the demographic data of these 17 patients, effects of inflammatory markers on overall survival (OS) and progression-free survival (PFS). Results: Ten women and seven men were included in this study. At the diagnosis, 6 patients were metastatic, 5 of them had received chemotherapy. There was no statistical difference in overall survival according to neutrophil/lymphocyte ratio (N/L) and platelet/lymphocyte (T/L) ratio. Conclusion: Primary surgery is the most effective treatment, If possible, metastasectomy should be performed. ACC is a chemotherapy-resistant disease, so chemotherapy should only be given to metastatic, symptomatic, and fıt patients. We did not detect the prognostic effect of T/L and N/L in a limited number of ACC samples. Keywords: Adenoid cystic carcinoma, inflammatory markers, salivary gland, treatment
Cite This Article
Alandag C, Kazaz S, Cobanoglu B. Adenoid Cystic Carcinoma; A Single Center 15 Years Experience and Literature Review. EJMI. 2021; 5(4): 491-495
Corresponding Author: Celal Alandag